Jamal Rana: The LDL Cholesterol Goal Post Has Moved
Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:
”Goal post to treat LDL cholesterol has moved in patients with high risk for heart disease. Was thrilled to be part of The Wall Street Journal coverage of the biggest trials presented at AHA Scientific Sessions. We are now in era where multiple options exist to aggressively treat LDL cholesterol in high risk patients to prevent heart disease.
A PCSK9 inhibitor, evolocumab or Repatha, used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo when used in patients without a prior history of myocardial infarction or stroke, the VESALIUS-CV study shows over a median follow-up of 4.6 years.
A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial. IV CTX310 is an in vivo CRISPR-Cas9 gene-editing drug product targeting ANGPTL3.
CORALreef Lipids trial demonstrated that treatment with enlicitide decanoate, once-daily oral PCSK9-inhibitor, resulted in a statistically significant and clinically meaningful reduction in LDL cholestrol.”
Check here for more information.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk